Chemistry:Azelaprag
From HandWiki
Azelaprag (original Amgen development code AMG 986, subsequently licensed to BioAge Labs and renamed BGE-105) is a drug which is a selective, small-molecule agonist for the apelin receptor. It was originally developed as a potential treatment for heart failure and has subsequently been investigated for other applications such as obesity and muscle wasting in elderly or bed-bound patients.[1][2][3]
See also
- AM-8123
- BMS-986224
- CMF-019
References
- ↑ "Cardiovascular response to small-molecule APJ activation". JCI Insight 5 (8). April 2020. doi:10.1172/jci.insight.132898. PMID 32208384.
- ↑ "Safety, tolerability, pharmacokinetics, and pharmacodynamics of AMG 986, a novel small molecule apelin receptor agonist, in healthy subjects and heart failure patients.". Journal of Cardiac Failure 26 (10): S68. October 2020. doi:10.1016/j.cardfail.2020.09.200.
- ↑ "Identification of 6-Hydroxypyrimidin-4(1H)-one-3-carboxamides as Potent and Orally Active APJ Receptor Agonists". ACS Medicinal Chemistry Letters 12 (11): 1766–1772. November 2021. doi:10.1021/acsmedchemlett.1c00385. PMID 34795866.
 |  |
